These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3496152)

  • 1. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
    Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
    Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1.
    Fujimiya Y; Bakke A; Chang WC; Linker-Israeli M; Udis B; Horwitz D; Pattengale PK
    Int J Cancer; 1986 May; 37(5):639-49. PubMed ID: 3457769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells.
    van de Griend RJ; van Krimpen BA; Ronteltap CP; Bolhuis RL
    J Immunol; 1984 Jun; 132(6):3185-91. PubMed ID: 6233369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
    Chang WC; Fujimiya Y; Casteel N; Pattengale P
    Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of HNK-1+ (Leu-7) human lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic capability.
    Abo T; Cooper MD; Balch CM
    J Immunol; 1982 Oct; 129(4):1752-7. PubMed ID: 6980948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
    Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
    Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro expansion and analysis of cloned cytotoxic T cells derived from patients with chronic T gamma lymphoproliferative disorders.
    van de Griend RJ; Bolhuis RL
    Blood; 1985 Apr; 65(4):1002-9. PubMed ID: 3872139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
    J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.
    Somasundaram R; Advani SH; Gangal SG
    Cancer Immunol Immunother; 1988; 27(2):183-9. PubMed ID: 3262015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
    Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
    Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cytotoxicity and transplantation protection by autologous natural and activated killer cells against an in vitro transformed tumorigenic fibroblast line. A case study.
    Wilhelm SA; Mukherji B
    J Clin Invest; 1985 Apr; 75(4):1162-8. PubMed ID: 3988936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phorbol ester induces a differential effect on the effector function of human allospecific cytotoxic T lymphocyte and natural killer clones.
    Bensussan A; Tourvieille B; Chen LK; Dausset J; Sasportes M
    Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6642-6. PubMed ID: 3876559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.